TY - JOUR T1 - Clinicopathological Features in Elderly ALK-rearranged Non-small Cell Lung Cancer Patients JF - In Vivo JO - In Vivo SP - 2001 LP - 2007 DO - 10.21873/invivo.11998 VL - 34 IS - 4 AU - KUNIHIKO MIYAZAKI AU - SHINYA SATO AU - TAKAHIDE KODAMA AU - TAKESHI NUMATA AU - TAKEO ENDO AU - YUSUKE YAMAMOTO AU - KEI SHIMIZU AU - HIDEYASU YAMADA AU - KENJI HAYASHIHARA AU - SHINICHIRO OKAUCHI AU - HIROAKI SATOH AU - YUTAKA YAMADA AU - TOMOHIRO TAMURA AU - KAZUTO SAITO AU - NORIHIRO KIKUCHI AU - KOICHI KURISHIMA AU - HIROICHI ISHIKAWA AU - HIROKO WATANABE AU - TOSHIHIRO SHIOZAWA AU - NOBUYUKI HIZAWA AU - YASUNORI FUNAYAMA AU - SHIGEN HAYASHI AU - HIROYUKI NAKAMURA AU - TAKAAKI YAMASHITA Y1 - 2020/07/01 UR - http://iv.iiarjournals.org/content/34/4/2001.abstract N2 - Aim: To clarify the clinicopathological features in elderly anaplastic lymphoma kinase (ALK) rearranged non-small cell lung cancer (NSCLC) patients. Patients and Methods: A retrospective study was performed in 129 ALK rearranged NSCLC patients diagnosed between April 2008 and March 2019 in fifteen Institutions of the Ibaraki prefecture, Japan. Results: Median age of patients was 63 years. In 59 patients aged 65 and older, the proportions of patients with advanced stage and those treated with ALK-tyrosine kinase inhibitor (TKI) were lower than those younger than 65 years. There was no difference in overall survival (OS) between the two age groups. Among the elderly patients, no difference was observed in OS between the patients aged 65-69 and those aged 70 and older. In 89 patients treated with TKI, no significant differences were observed in the progression-free survival of TKIs and OS between patients aged 65 and older and those younger than 65, respectively. Conclusion: Evaluation of ALK gene status and TKI treatment are desirable even for elderly patients. ER -